{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:41Z","timestamp":1772166461430,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["...."],"award-info":[{"award-number":["...."]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Patient-reported outcomes measures, such as those provided by\n                      <jats:italic>the Psoriatic Arthritis Impact of Disease (<\/jats:italic>\n                      PsAID) questionnaire, have been found to be a reliable indicator of change during treatment, predictive of long-term outcomes, and the impact of psoriatic arthritis (PsA) on patients\u2019 lives. The objective of the study was to describe the demographic and clinical characteristics of PsA patients with a low disease impact and to analyze predictive factors for that state.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post hoc analysis of a cross-sectional multicenter study that included 223 consecutive patients. PsAID questionnaire was used to estimate disease impact. Patients with a PsAID &lt;\u20094 were considered in low disease impact. Minimal disease activity (MDA) response and the Health Assessment Questionnaire (HAQ) were also assessed. The degree of agreement between the different outcomes was addressed by Cohen\u2019s kappa index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred and twenty-two (54.7%) patients reached a PsAID &lt;\u20094. Among them, 52.0% and 68.0% presented articular or skin remission, respectively. Almost 75% of patients were in MDA state and 85.2% presented a low disability state according to the HAQ. A moderate concordance between HAQ \u2264\u20090.5 and PsAID &lt;\u20094 (\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u20090.53), fair between MDA and PsAID &lt;\u20094 (\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u20090.36), and moderate between DAPSA remission and PsAID &lt;\u20094 (\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u20090.46) was observed. Multivariate logistic regression analysis showed that patients with distal interphalangeal joint (DIP) disease (OR 0.40, 95%CI, 0.20\u20130.79,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009), family history of PsA (OR 0.25, 95%CI, 0.09\u20130.72,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010), and higher C-reactive protein (OR 0.92, 95%CI, 0.85\u20130.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036) were significantly less likely to reach a PsAID &lt;\u20094.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is certain discrepancy between disease activity measures and a low impact of disease in PsA. Clinical features (DIP joint involvement), biologic activity, and genetic factors (familial history) seem to be associated with lower odds of reaching a low disease impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02168-1","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T13:02:39Z","timestamp":1586955759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study"],"prefix":"10.1186","volume":"22","author":[{"name":"on behalf of the MAAPS study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Ruben","family":"Queiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"C\u00e1bez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"3","key":"2168_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10067-006-0298-y","volume":"26","author":"P Borman","year":"2007","unstructured":"Borman P, Toy GG, Babaoglu S, Bodur H, Ciliz D, Alli N. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin.Rheumatol. 2007;26(3):330\u20134.","journal-title":"Clin.Rheumatol."},{"issue":"6","key":"2168_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acr.22529","volume":"67","author":"A Haddad","year":"2015","unstructured":"Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ, Gladman DD. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res. 2015;67(6):842\u20137.","journal-title":"Arthritis Care Res"},{"key":"2168_CR3","doi-asserted-by":"crossref","unstructured":"Johnson K, Ye JY, Chandran V, Gladman DD. A novel role for the psoriatic arhtirtis impact of disease (PsAID) questionnaire. Semin Arthritis Rheum. 2019;49(2):241\u201345.","DOI":"10.1016\/j.semarthrit.2019.04.001"},{"issue":"10","key":"2168_CR4","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","volume":"44","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A. Updating the Psoriatic Arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. J Rheumatol. 2017 Oct;44(10):1522\u20138.","journal-title":"J Rheumatol"},{"issue":"3","key":"2168_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/annrheumdis-2017-211996","volume":"77","author":"R Holland","year":"2018","unstructured":"Holland R, Tillett W, Korendowych E, Cavill C, Waldron N, Brooke M, McHugh NJ. Validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire and its potential as a single-item outcome measure in clinical practice. Ann.Rheum.Dis. 2018;77(3):343\u20137.","journal-title":"Ann.Rheum.Dis."},{"issue":"6","key":"2168_CR6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de WM KU, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooaar I, Heiberg T, Bertheussen H, Canete JD, Sanchez LA, Balanescu A, Dinte A, de VK SJS, Stamm T, Niedermayer D, Bekes G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2168_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3899\/jrheum.131312","volume":"41","author":"JR Kirwan","year":"2014","unstructured":"Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, Choy E, de Wit M, Guillemin F, Hewlett S, Kvien TK, Landewe RB, Leong AL, Lyddiatt A, March L, May J, Montie PL, Nikai E, Richards P, Voshaar MM, Smeets W, Strand V, Tugwell P, Gossec L. Updating the OMERACT filter: implications for patient-reported outcomes. J Rheumatol. 2014;41(5):1011\u20135.","journal-title":"J Rheumatol"},{"issue":"9","key":"2168_CR8","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/art.34543","volume":"64","author":"P Studenic","year":"2012","unstructured":"Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 2012;64(9):2814\u201323.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2168_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jpainsymman.2015.12.309","volume":"51","author":"K Webber","year":"2016","unstructured":"Webber K, Davies AN, Cowie MR. Disparities between clinician and patient perception of breakthrough pain control. J Pain SymptomManage. 2016;51(5):933\u20137.","journal-title":"J Pain SymptomManage"},{"issue":"10","key":"2168_CR10","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/acr.23172","volume":"69","author":"C Desthieux","year":"2017","unstructured":"Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scrivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L. Determinants of patient-physician discordance in global assessment in psoriatic arthritis: a multicenter European study. Arthritis Care Res. 2017;69(10):1606\u201311.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"2168_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13075-017-1277-1","volume":"19","author":"R Queiro","year":"2017","unstructured":"Queiro R, Ca\u00f1ete JD, Montilla C, Abad M, Montoro M, Gomez S, Cabez A. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis ResTher. 2017;19(1):72.","journal-title":"Arthritis ResTher"},{"issue":"8","key":"2168_CR12","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2168_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann.Rheum.Dis. 2010;69(1):48\u201353.","journal-title":"Ann.Rheum.Dis."},{"issue":"5","key":"2168_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2168_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.semarthrit.2017.09.002","volume":"47","author":"P Hojgaard","year":"2018","unstructured":"Hojgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R. A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative. Semin Arthritis Rheum. 2018;47(5):654\u201365.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2168_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","volume":"78","author":"C Gorlier","year":"2019","unstructured":"Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Canete JD, Scrivo R, Balanescu A, Dernis E, Talli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Ann.Rheum.Dis. 2019;78(2):201\u20138.","journal-title":"Ann.Rheum.Dis."},{"issue":"2","key":"2168_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jbspin.2018.06.003","volume":"86","author":"R Queiro","year":"2019","unstructured":"Queiro R. Remission and stringent treatment goals in psoriatic arthritis: doctors\u2019 opinion is not enough. Joint Bone Spine. 2019;86(2):269\u201370.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"2168_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/rheumatology\/kex183","volume":"57","author":"LJJ van Mens","year":"2018","unstructured":"van Mens LJJ, Turina MC, van de Sande MGH, Nurmohamed MT, van Kuijk AWR, Baeten DLP. Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement. Rheumatology. 2018;57(2):283\u201390.","journal-title":"Rheumatology"},{"issue":"1","key":"2168_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, FVD B, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2168_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"5","key":"2168_CR21","first-page":"808","volume":"37","author":"S Bakirci","year":"2019","unstructured":"Bakirci S, Solmaz D, Al Osaimi N, Dalkilic E, Can M, Erden A, Ozisler C, Cinar M, Kilic L, Kucuk A, Omma A, Yildiz F, Dogru A, Tufan A, Esmen SE, Akar S, Kalyoncu U, Aydin SZ, PsArt-ID (Psoriatic Arthritis-International Database). What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life? Clin Exp Rheumatol. 2019;37(5):808\u201312.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2168_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/art.1780380619","volume":"38","author":"DD Gladman","year":"1995","unstructured":"Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum. 1995;38(6):845\u201350.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2168_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.22443","volume":"56","author":"JA Husted","year":"2007","unstructured":"Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum. 2007;56(3):840\u20139.","journal-title":"Arthritis Rheum"},{"key":"2168_CR24","doi-asserted-by":"publisher","unstructured":"Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, Palominos PE, Canete JD, Scrivo R, Balanescu A, Dernis E, Talli S, Ruyssen-Witrand A, Soubrier M, Aydin S, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L. Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with gender in 458 patients from 14 countries. Arthritis Care Res. 2019. https:\/\/doi.org\/10.1002\/acr.24090.","DOI":"10.1002\/acr.24090"},{"issue":"6","key":"2168_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.reuma.2015.12.005","volume":"12","author":"E Gal\u00cdndez","year":"2016","unstructured":"Gal\u00cdndez E, Carmona L. Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatol.Clin. 2016;12(6):307\u201312.","journal-title":"Reumatol.Clin."},{"issue":"3","key":"2168_CR26","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10067-018-4004-7","volume":"37","author":"R Queiro","year":"2018","unstructured":"Queiro R, Ca\u00f1ete JD. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association? Clin.Rheumatol. 2018;37(3):661\u20136.","journal-title":"Clin.Rheumatol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02168-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02168-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02168-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:27:54Z","timestamp":1618432074000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02168-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2168"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02168-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.19994\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19994\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"28 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided their informed written consent. In accordance with the Spanish recommendations, the study was approved by the Clinical Research Ethics Committee of La Fe Hospital [ref number FPNT-07-14-EO (C)] and was conducted in accordance with the principles contained in the Declaration of Helsinki for studies in humans.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RQ has received fees for speaking and\/or consulting from Abbvie, Celgene, Janssen, MSD, Novartis, Pfizer, and Lilly.JDC has received fees for speaking and\/or consulting from AbbVie, Boehringer, Bristol, Celgene, Janssen, MSD\/Schering Plough, Novartis and Pfizer.MM, SG, and AC are employees of Pfizer, S.L.U.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}